141 related articles for article (PubMed ID: 34117845)
21. Xpr1 is an atypical G-protein-coupled receptor that mediates xenotropic and polytropic murine retrovirus neurotoxicity.
Vaughan AE; Mendoza R; Aranda R; Battini JL; Miller AD
J Virol; 2012 Feb; 86(3):1661-9. PubMed ID: 22090134
[TBL] [Abstract][Full Text] [Related]
22. Prediction Biomarkers Associated with Lymph Node Metastasis and Prognosis were Identified in Papillary Thyroid Carcinoma via Integrated Bioinformatics Analysis.
Gan S; Ye R; Ha Y; Xiong Y; Li R; Di X; Zou Z; Sun Y; Zhang Z
Comb Chem High Throughput Screen; 2021; 24(9):1395-1409. PubMed ID: 33155892
[TBL] [Abstract][Full Text] [Related]
23. Tripartite Motif Containing 3 inhibits the aggressive behaviors of papillary thyroid carcinoma and indicates lower recurrence risk.
Song Y; Gao Z; Yan Z; Zheng C
Genes Genomics; 2022 Apr; 44(4):455-465. PubMed ID: 34860317
[TBL] [Abstract][Full Text] [Related]
24. Decreased Expression of Estrogen Receptors Is Associated with Tumorigenesis in Papillary Thyroid Carcinoma.
Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162942
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance of DNMT3A alterations in Middle Eastern papillary thyroid carcinoma.
Siraj AK; Pratheeshkumar P; Parvathareddy SK; Bu R; Masoodi T; Iqbal K; Al-Rasheed M; Al-Dayel F; Al-Sobhi SS; Alzahrani AS; Al-Dawish M; Al-Kuraya KS
Eur J Cancer; 2019 Aug; 117():133-144. PubMed ID: 31280122
[TBL] [Abstract][Full Text] [Related]
26. Tumor promoting effects of glucagon receptor: a promising biomarker of papillary thyroid carcinoma via regulating EMT and P38/ERK pathways.
Jiang HC; Chen XR; Sun HF; Nie YW
Hum Cell; 2020 Jan; 33(1):175-184. PubMed ID: 31782107
[TBL] [Abstract][Full Text] [Related]
27. Relationship between genetic alterations and clinicopathological characteristics of papillary thyroid carcinoma.
Kure S; Wada R; Naito Z
Med Mol Morphol; 2019 Dec; 52(4):181-186. PubMed ID: 30788603
[TBL] [Abstract][Full Text] [Related]
28. Immune Cell Confrontation in the Papillary Thyroid Carcinoma Microenvironment.
Xie Z; Li X; He Y; Wu S; Wang S; Sun J; He Y; Lun Y; Zhang J
Front Endocrinol (Lausanne); 2020; 11():570604. PubMed ID: 33193087
[TBL] [Abstract][Full Text] [Related]
29. OGDHL closely associates with tumor microenvironment and can serve as a prognostic biomarker for papillary thyroid cancer.
Mao M; Huang RZ; Zheng J; Liang HQ; Huang WH; Liu J; Li JH
Cancer Med; 2021 Jan; 10(2):728-736. PubMed ID: 33405394
[TBL] [Abstract][Full Text] [Related]
30. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
31. Identifying the tumor-progressive gene expression profile in high-risk papillary thyroid cancer.
Shibata M; Inaishi T; Ichikawa T; Shimizu D; Soeda I; Takano Y; Takeuchi D; Tsunoda N; Kikumori T
Surg Today; 2021 Oct; 51(10):1703-1712. PubMed ID: 33733290
[TBL] [Abstract][Full Text] [Related]
32. Identification of Biomarkers Based on Differentially Expressed Genes in Papillary Thyroid Carcinoma.
Han J; Chen M; Wang Y; Gong B; Zhuang T; Liang L; Qiao H
Sci Rep; 2018 Jul; 8(1):9912. PubMed ID: 29967488
[TBL] [Abstract][Full Text] [Related]
33. BGL3 inhibits papillary thyroid carcinoma progression via regulating PTEN stability.
Zhao M; Yang F; Sang C; Yan C; Wang Z
J Endocrinol Invest; 2021 Oct; 44(10):2165-2174. PubMed ID: 33543443
[TBL] [Abstract][Full Text] [Related]
34. STAT3-induced upregulation of lncRNA ABHD11-AS1 promotes tumour progression in papillary thyroid carcinoma by regulating miR-1301-3p/STAT3 axis and PI3K/AKT signalling pathway.
Wen J; Wang H; Dong T; Gan P; Fang H; Wu S; Li J; Zhang Y; Du R; Zhu Q
Cell Prolif; 2019 Mar; 52(2):e12569. PubMed ID: 30657221
[TBL] [Abstract][Full Text] [Related]
35. Mapping the Molecular Basis and Markers of Papillary Thyroid Carcinoma Progression and Metastasis Using Global Transcriptome and microRNA Profiling.
Akyay OZ; Gov E; Kenar H; Arga KY; Selek A; Tarkun İ; Canturk Z; Cetinarslan B; Gurbuz Y; Sahin B
OMICS; 2020 Mar; 24(3):148-159. PubMed ID: 32073999
[TBL] [Abstract][Full Text] [Related]
36. Identification and analysis of genes associated with papillary thyroid carcinoma by bioinformatics methods.
Zhang S; Wang Q; Han Q; Han H; Lu P
Biosci Rep; 2019 Apr; 39(4):. PubMed ID: 30872410
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of serum lncRNA-ABHD11-AS1 as poor prognosis of patients with papillary thyroid carcinoma.
Hou S; Zhuang YY; Lin QY; Chen Z; Zhao HG; Zhang L; Lin CH
Exp Mol Pathol; 2021 Aug; 121():104658. PubMed ID: 34102210
[TBL] [Abstract][Full Text] [Related]
38. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
39. Role of differentially expressed genes and long non-coding RNAs in papillary thyroid carcinoma diagnosis, progression, and prognosis.
Cai WY; Chen X; Chen LP; Li Q; Du XJ; Zhou YY
J Cell Biochem; 2018 Nov; 119(10):8249-8259. PubMed ID: 29968931
[TBL] [Abstract][Full Text] [Related]
40. Ferroptosis-related gene signature predicts the prognosis of papillary thyroid carcinoma.
Shi J; Wu P; Sheng L; Sun W; Zhang H
Cancer Cell Int; 2021 Dec; 21(1):669. PubMed ID: 34906147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
